Field notes from upstream of execution
Research from RŌG Health
Research briefs on commercial readiness, capital strategy, and the failure modes that stall medtech companies before they scale. Published periodically by RŌG Health.
The Pre-Diligence Discipline
Why the strongest medtech raise begins before the investor opens your deck
In a tighter capital environment, the commercial story carries weight it did not previously carry. Medtech diligence is structured tech-first; commercial story validation runs distantly behind. This brief argues for a discipline borrowed from adjacent industries — pre-diligence — and what it looks like for a medtech founder preparing to raise.
Read the briefThe Commercialization Readiness Gap in MedTech
What the evidence shows about where medtech stalls — and how to reduce avoidable commercial risk
Most medtech companies that stall do not stall on the technology. They stall at one of the gates between clearance and repeatable revenue — buyer clarity, evidence threshold, reimbursement friction, workflow adoption, and committee-based decision-making. This brief synthesizes the evidence on where those failures cluster.
Read the brief